Ascendis Pharma A/S $ASND Shares Sold by Perceptive Advisors LLC

Perceptive Advisors LLC lessened its holdings in shares of Ascendis Pharma A/S (NASDAQ:ASND) by 0.7% in the fourth quarter, according to its most recent filing with the SEC. The firm owned 1,081,421 shares of the biotechnology company’s stock after selling 7,080 shares during the period. Ascendis Pharma A/S accounts for 4.1% of Perceptive Advisors LLC’s portfolio, making the stock its 4th largest position. Perceptive Advisors LLC’s holdings in Ascendis Pharma A/S were worth $230,602,000 as of its most recent SEC filing.

Other institutional investors have also recently bought and sold shares of the company. HighVista Strategies LLC grew its holdings in shares of Ascendis Pharma A/S by 138.1% in the 3rd quarter. HighVista Strategies LLC now owns 7,082 shares of the biotechnology company’s stock valued at $1,408,000 after buying an additional 4,108 shares during the period. American Century Companies Inc. grew its holdings in shares of Ascendis Pharma A/S by 2.6% in the 3rd quarter. American Century Companies Inc. now owns 544,606 shares of the biotechnology company’s stock valued at $108,274,000 after buying an additional 13,797 shares during the period. Hudson Bay Capital Management LP acquired a new position in shares of Ascendis Pharma A/S in the 3rd quarter valued at $15,693,000. Avoro Capital Advisors LLC grew its holdings in shares of Ascendis Pharma A/S by 2.6% in the 3rd quarter. Avoro Capital Advisors LLC now owns 5,110,000 shares of the biotechnology company’s stock valued at $1,015,919,000 after buying an additional 130,000 shares during the period. Finally, Fred Alger Management LLC grew its holdings in shares of Ascendis Pharma A/S by 4,398.1% in the 3rd quarter. Fred Alger Management LLC now owns 170,701 shares of the biotechnology company’s stock valued at $33,937,000 after buying an additional 166,906 shares during the period.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on ASND shares. Wall Street Zen raised shares of Ascendis Pharma A/S from a “hold” rating to a “buy” rating in a report on Saturday, May 9th. Wells Fargo & Company decreased their price target on shares of Ascendis Pharma A/S from $330.00 to $326.00 and set an “overweight” rating for the company in a report on Friday, May 8th. Bank of America boosted their price target on shares of Ascendis Pharma A/S from $262.00 to $292.00 and gave the company a “buy” rating in a report on Thursday, April 16th. Barclays boosted their price target on shares of Ascendis Pharma A/S from $342.00 to $345.00 and gave the company an “overweight” rating in a report on Monday, May 11th. Finally, Royal Bank Of Canada boosted their price target on shares of Ascendis Pharma A/S from $250.00 to $275.00 and gave the company an “outperform” rating in a report on Monday, March 2nd. Two investment analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Ascendis Pharma A/S has a consensus rating of “Buy” and a consensus price target of $295.39.

Ascendis Pharma A/S Price Performance

Shares of NASDAQ ASND opened at $231.15 on Thursday. The firm has a market cap of $14.42 billion, a PE ratio of 26.66 and a beta of 0.39. The company has a current ratio of 1.00, a quick ratio of 0.72 and a debt-to-equity ratio of 0.79. Ascendis Pharma A/S has a 1-year low of $160.86 and a 1-year high of $250.74. The company has a fifty day moving average price of $232.16 and a 200 day moving average price of $224.09.

Ascendis Pharma A/S (NASDAQ:ASND) last announced its earnings results on Thursday, May 7th. The biotechnology company reported $0.32 earnings per share for the quarter, topping analysts’ consensus estimates of $0.21 by $0.11. The company had revenue of $285.45 million during the quarter, compared to analyst estimates of $362.47 million. Research analysts predict that Ascendis Pharma A/S will post 14.25 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, insider Flemming Steen Jensen sold 19,460 shares of the company’s stock in a transaction on Monday, May 11th. The shares were sold at an average price of $238.49, for a total value of $4,641,015.40. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Jean Jacques Bienaime bought 400 shares of Ascendis Pharma A/S stock in a transaction that occurred on Tuesday, May 26th. The stock was bought at an average cost of $237.80 per share, with a total value of $95,120.00. Following the completion of the purchase, the director owned 400 shares in the company, valued at approximately $95,120. This trade represents a ? increase in their position. The disclosure for this purchase is available in the SEC filing. 40.00% of the stock is currently owned by corporate insiders.

About Ascendis Pharma A/S

Ascendis Pharma A/S is a Denmark?based biopharmaceutical company focused on developing innovative therapies for rare endocrine diseases. Founded in 2015 and headquartered in Hellerup, the company leverages its proprietary TransCon drug delivery platform to create long?acting prodrugs designed to improve safety, efficacy and patient convenience. Ascendis Pharma maintains research and development operations in Europe and the United States, with clinical studies spanning North America, Europe and Asia.

The company’s lead product, lonapegsomatropin (Skytrofa®), is a once?weekly growth hormone therapy approved by the U.S.